` 688506 (Sichuan Biokin Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

688506
vs
Shanghai Composite

Over the past 12 months, has significantly outperformed Shanghai Composite, delivering a return of 96% compared to the Shanghai Composite's 7% growth.

Stocks Performance
688506 vs Shanghai Composite

Loading

Performance Gap
688506 vs Shanghai Composite

Loading
688506
Shanghai Composite
Difference

Performance By Year
688506 vs Shanghai Composite

Loading
688506
Shanghai Composite
Add Stock

Competitors Performance
Sichuan Biokin Pharmaceutical Co Ltd vs Peers

Shanghai Composite
688506
LLY
JNJ
NOVO B
ROG
Add Stock

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
113.5B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
106.46 CNY
Overvaluation 62%
Intrinsic Value
Price
S
Back to Top